OTC · FNCH
Healthcare · Biotechnology
$10.20
Up+$0.10 (+0.99%)
Updated Sep 19, 2026, 8:17 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
FNCH does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning FNCH.
FNCH research
Company profile and research snapshot.
FINCH THERAPEUTCS GRP INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 12, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 9, 2022 | HC Wainwright & Co. | Buy | — |
| Apr 4, 2022 | Jefferies | Buy | — |
| Apr 13, 2021 | Evercore ISI Group | Outperform | — |
| Apr 13, 2021 | Jefferies | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 15, 2025
Finch, a legal tech startup, secured $20 million in funding to automate pre-litigation administrative tasks for personal injury law firms using AI and experienced paralegals, enabling firms to handle more cases efficiently.
GlobeNewswire Inc. · Jun 9, 2023
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch’s Annual Meeting of Stockholders held on June 8, 2023. The reverse stock split is intended to increase the per share trading price of Finch’s common stock to enable Finch to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market. Finch expects that, upon the opening of trading on June 12, 2023, its common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis under the current trading symbol “FNCH” and the CUSIP number 31773D200.
GlobeNewswire Inc. · May 10, 2023
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates.
GlobeNewswire Inc. · Apr 18, 2023
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has entered into a clinical trial agreement with Brigham and Women’s Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in ulcerative colitis. The Company also announced updates to its license agreement with the University of Minnesota.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FNCH.
No results
No recent SID articles mention FNCH.
